💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Metropolis Healthcare Limited is engaged in providing diagnostic services to patients, healthcare providers, and corporates across India and Africa. The Company has a single operating segment, namely Pathology services. It is engaged in the business of running laboratories…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, steadily growing business, fairly priced.
Metropolis Healthcare is scored on the pharma / healthcare framework. It keeps a healthy 11.4% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.83× reported profit. Free cash flow is worth about 1.1% of its market value.
Over the last 3 years revenue compounded at 13%/yr and profit at 10%/yr. Book value itself has compounded 16%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 13.7%. In the latest quarter profit grew 12% versus the prior quarter.
At 62× earnings, the stock sits at the 40th percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price already implies ~22%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 52.42 | 75.62 | better |
| P/B | 7.2 | 3.49 | worse |
| EV/EBITDA | 25.62 | 19.95 | worse |
| ROE | 13.66 | — | — |
| ROCE | 17.47 | 10.81 | better |
| ROA | 9.63 | 3.84 | better |
| Quick Ratio | 1.27 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 13% CAGR over 3 years — steady double-digit compounder. Growth is accelerating — latest year outpaced the prior year's rate.
The latest year saw a +31% swing — check if it's a one-off or structural.
Operating margins have been stable around 16% — no major structural shift. Margins have declined for 2 consecutive years — watch for a structural cost problem.
ROE at 13% — a respectable return on shareholder capital. Low variance across years — a predictable business that earns steadily on its equity base.
Profit grew faster than EPS (10% vs -31%) — share dilution is eroding per-share value. -31% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.8× PAT — earnings are well-backed by cash; strong accrual quality. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 5% sequentially — momentum is building. Low quarterly variance (9% spread) — a predictable, non-seasonal revenue stream.
Profit jumped 12% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 47.8% — dispersed ownership; institutional flows drive the stock. Promoters reduced 1.1pp over 4 quarters — watch whether this is planned divestment or pledge invocations. Both FII and MF added last quarter — broad institutional confidence.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.